Clinical Trial Site

Stockholm 17164

3 studies enrolling now · 8 studies all time

What they study most

ALA Dehydratase Deficient Porphyria (ADP), ANCA-Associated Vasculitis, Acute Hepatic Porphyria, Acute Intermittent Porphyria, Acute Porphyria, Hereditary Coproporphyria (HCP), Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Porphyria, Acute Intermittent, Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Studies at this site

• TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) — Recruiting now
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) — Completed
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) — Completed
• A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) — Completed
• A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) — Completed